2013
DOI: 10.1111/1744-9987.12013
|View full text |Cite
|
Sign up to set email alerts
|

Hemoglobin Maintenance and Dosing Strategies Using Intravenous Continuous Erythropoietin Receptor Activator in Japanese Hemodialysis Patients

Abstract: Methoxy polyethylene glycol-epoetin beta, a continuous erythropoietin receptor activator (CERA), is reported to be effective in managing renal anemia but there is little data about CERA in Japan. This study aimed to ascertain the effects of CERA in Japanese hemodialysis patients and the appropriate starting dose of CERA when switching from other erythropoiesis-stimulating agents. We switched 61 stable hemodialysis patients to 4-weekly intravenous CERA, from either epoetin beta (rHuEPO) or darbepoetin alpha (DA… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
4
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 22 publications
1
4
0
Order By: Relevance
“…The mean ERI values had also significantly decreased at the end of the follow-up period. These findings support the results of a previous study by Hirai et al [15]. We used the manufacturer's recommended starting dose of CERA when we switched the patients from DA to CERA.…”
Section: Discussionsupporting
confidence: 91%
“…The mean ERI values had also significantly decreased at the end of the follow-up period. These findings support the results of a previous study by Hirai et al [15]. We used the manufacturer's recommended starting dose of CERA when we switched the patients from DA to CERA.…”
Section: Discussionsupporting
confidence: 91%
“…For example, in stable HD patients, a couple of studies have suggested decreasing CERA doses over time, whereas others argue for increasing dosages 52,53. A study conducted with 52 Japanese HD patients showed that CERA doses decreased during a 28-week study 52.…”
Section: Discussionmentioning
confidence: 99%
“…For example, in stable HD patients, a couple of studies have suggested decreasing CERA doses over time, whereas others argue for increasing dosages 52,53. A study conducted with 52 Japanese HD patients showed that CERA doses decreased during a 28-week study 52. In contrast, the randomized comparative PATRONUS (comPArator sTudy of CERA and darbepOetin alfa in patieNts Undergoing dialySis) trial53 conducted with 490 HD patients demonstrated a dose increase of 6.8% after switching from once-weekly DA to once-monthly CERA.…”
Section: Discussionmentioning
confidence: 99%
“…The blood level may have stabilized earlier in the early phase after switching in the Q2W group and inhibited rebound of the hepcidin level through stabilization of the hematopoietic action. In addition, Rice et al reported that an intravenous administration-induced decrease in the blood EPO level induced the apoptosis (neocytolysis) of young red blood cells immediately after release from the bone marrow [18]. It was also suggested that early stabilization of the blood level by every-2-week administration in the early phase was also involved in the stabilization of the Hb level and CERA dose reduction through the inhibition of neocytolysis.…”
Section: Discussionmentioning
confidence: 99%